# US 2025/0145954 A1 · Expansion of human hematopoietic stem cells from human yellow bone marrow

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145954 A1
- Document ID: US20250145954A1
- Status: Published application
- Kind: A1
- Application number: 18/833,774
- Filed: 2023-01-30
- Published: 2025-05-08
- Earliest claimed: 2022-01-28
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Tammy NGUYEN; Silvia CORVERA; Tiffany DESOUZA; Anand DESAI
- Web page: https://patentgrep.com/patent/US20250145954A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2513/00: 3D culture
- C12N 2533/50: Proteins
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Hematopoietic stem cells (HSC) are essential to developing a functional immune system, including monocyte-macrophage cells required for wound healing. Described herein are methods of using yellow bone marrow as a source of cells to generate hematopoietic stem cells. The methods include expansion of human hematopoietic stem cells by culture of human yellow bone marrow in 3-dimensional hydrogel and pro-angiogenic, stem cell-promoting medium.

## Claims

### Claim 1

A method of obtaining a population of hematopoietic stem cells (HSCs), the method comprising:
providing a sample comprising yellow bone marrow from a subject;
dividing the sample into pieces each about 0.5-2 mm3, preferably about 1 mm3;
embedding the pieces in a hydrogel with media for expansion of HSCs;
maintaining the pieces in culture for a time sufficient for expansion of the HSCs, and isolating the HSCs from the hydrogel,
thereby obtaining a population of HSCs.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is from a long bone of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is a mammal, e.g., a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hydrogel comprises MATRIGEL.

### Claim 5 (depends on 1)

The method of claim 1, wherein the media for expansion of HSCs comprises:
(i) pro-angiogenic factors, preferably EGF, IGF, VEGF, and FGFb;
(ii) stem cell promoting factors, preferably stem cell factor (SCF), and optionally
(iii) one or more of thrombopoietin (TPO), fms related receptor tyrosine kinase 3 (Flt3), Interleukin 6 (IL6), an aryl hydrocarbon receptor (AHR) antagonist; and/or UM729.

### Claim 6 (depends on 5)

The method of claim 5, wherein the AHR antagonist is StemRegenin 1 (SR1).

### Claim 7 (depends on 1)

The method of claim 1, wherein the pieces are maintained in culture for at least 10, 12, or 14 days, or up to 17, 18, 20, or 24 days.

### Claim 8 (depends on 1)

The method of claim 1, further comprising isolating cells that are CD34+, CD45dim, CD90+, CD38−, and/or Lineage−, optionally using cell sorting or magnetic beads.

### Claim 9 (depends on 1)

The method of claim 1, wherein the population comprises 10,000-20,000 HSCs.

### Claim 10 (depends on 1)

The method of claim 1, further comprising culturing the population of HSCs under conditions sufficient for differentiation into erythroid progenitor cells, granulocyte-macrophage progenitor cells, multipotential granulocyte, erythroid, macrophage, megakaryocyte progenitor cells, and/or lymphoid progenitor cells (Common Lymphoid Progenitors (CLPs)), or to B cells, T cells, or NK cells.

### Claim 11 (depends on 1)

A method of treating a subject, the method comprising:
obtaining a population of HSCs by the method of claim 1;
differentiating the HSCs into a selected erythroid, lymphoid, or myeloid cell type;
and administering the differentiated cells to the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the yellow bone marrow is obtained from the subject to be treated.

### Claim 13 (depends on 11)

The method of claim 11, wherein the subject is diabetic and has a wound, and the cells are differentiated.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cells are differentiated to immune cells, preferably to monocytes and/or macrophages, and administered to the wound.

### Claim 15 (depends on 1)

A population of HSCs obtained by the method of claim 1.

### Claim 16

(canceled)

### Claim 17 (depends on 10)

A population of cells comprising erythroid progenitor cells, granulocyte-macrophage progenitor cells, multipotential granulocyte, erythroid, macrophage, megakaryocyte progenitor cells, lymphoid progenitor cells (Common Lymphoid Progenitors (CLPs)), B cells, T cells, or NK cells, obtained by the method of claim 10.

### Claim 18

(canceled)
